SCHEMBL17858628

SCHEMBL17858628

Cc1cncc(NS(=O)(=O)c2cccc(F)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.54
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
PGR P06401 1/20 0.51
SLC10A2 Q12908 1/20 0.50
SLC10A1 Q14973 1/20 0.50
SLC10A6 Q3KNW5 1/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PRF1 P14222 1/20 0.48
PIK3CB P42338 3/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17858621 0.84 MEN1 (0.60) SLC22A12KMT2AMEN1LMNASMN1; SMN2
SCHEMBL13539327 0.84 SLC22A12 (0.60) SLC22A12KMT2AMEN1PIK3CBTSHR
SCHEMBL22914714 0.83 PGR (0.50) KMT2AMEN1PGRLMNASMN1; SMN2
SCHEMBL19728992 0.83 PIK3CB (0.50) SLC22A12KMT2APGRLMNASMN1; SMN2
SCHEMBL13807498 0.81 PGR (0.68) KMT2AMEN1PGRLMNASMN1; SMN2
SCHEMBL21083146 0.81 PRF1 (0.47) KMT2APGRLMNASMN1; SMN2PRF1
SCHEMBL16020319 0.80 MEN1 (0.62) KMT2AMEN1TSHRALDH1A1POLB
SCHEMBL23565665 0.80 KMT2A (0.71) KMT2AMEN1PGRLMNASMN1; SMN2
SCHEMBL11918322 0.78 PIK3CB (0.64) SLC22A12PRF1PIK3CB
SCHEMBL9517147 0.78 PGR (0.54) SLC22A12KMT2AMEN1PGRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170360788-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-12-21 US disclosed
WO-2016100347-A2 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360788-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K EGFR, ERBB2, ERBB3 SLC22A12 2643/4885KMT2A 2786/4885MEN1 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.